US Pharma MarketingThe post First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial appeared first on Clinical Trials Arena.
First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial
Triveni Bio has dosed the first healthy volunteers in its Phase I study of TRIV-573, a half-life extended bispecific antibody aimed at KLK5/7 and IL-13. Triveni Bio’s lead programme, TRIV-509, is in Phase II trial for atopic dermatitis, with results expected by 2026-end. The trial uses KLK5/7 inhibition for barrier repair with IL-13 blockade, seeking to address unmet needs in atopic dermatitis. Credit: PeopleImages / Shutterstock.com. Triveni Bio has dosed the first healthy volunteers in its Phase I study of TRIV-573, a half-life extended bispecific antibody aimed at kallikreins 5 and 7 (KLK5/7) and interleukin 13 (IL-13). With the ongoing…
Triveni Bio has dosed the first healthy volunteers in its Phase I study of TRIV-573, a half-life extended bispecific antibody aimed at KLK5/7 and IL-13.
Source: Clinical Trials Arena